Nurix Therapeutics (NRIX) Enterprise Value (2019 - 2025)
Historic Enterprise Value for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to -$592.9 million.
- Nurix Therapeutics' Enterprise Value rose 273.01% to -$592.9 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$592.9 million, marking a year-over-year increase of 273.01%. This contributed to the annual value of -$592.9 million for FY2025, which is 273.01% up from last year.
- Per Nurix Therapeutics' latest filing, its Enterprise Value stood at -$592.9 million for Q4 2025, which was up 273.01% from -$428.8 million recorded in Q3 2025.
- In the past 5 years, Nurix Therapeutics' Enterprise Value registered a high of -$244.0 million during Q1 2024, and its lowest value of -$609.6 million during Q4 2024.
- Moreover, its 5-year median value for Enterprise Value was -$326.5 million (2021), whereas its average is -$372.4 million.
- As far as peak fluctuations go, Nurix Therapeutics' Enterprise Value surged by 2485.67% in 2023, and later crashed by 12528.52% in 2025.
- Nurix Therapeutics' Enterprise Value (Quarter) stood at -$295.7 million in 2021, then fell by 4.54% to -$309.1 million in 2022, then increased by 6.87% to -$287.9 million in 2023, then plummeted by 111.73% to -$609.6 million in 2024, then increased by 2.73% to -$592.9 million in 2025.
- Its last three reported values are -$592.9 million in Q4 2025, -$428.8 million for Q3 2025, and -$485.8 million during Q2 2025.